ICE
55
2
CME
61
2
ISRG
70
4
COF
52
5
ORCL
55
6
MCK
59
3
PX
58
5
MCHP
37
3
ROST
62
2
SE
60
3
ROK
48
2
R
61
2
NUE
41
2
ADI
59
2
INTU
57
3
QRVO
20
2
PLD
40
2
GOOGL
66
2
MAT
43
2
DNB
56
2
ICE
55
2
CME
61
2
ISRG
70
4
COF
52
5
ORCL
55
6
MCK
59
3
PX
58
5
MCHP
37
3
ROST
62
2
SE
60
3
ROK
48
2
R
61
2
NUE
41
2
ADI
59
2
INTU
57
3
QRVO
20
2
PLD
40
2
GOOGL
66
2
MAT
43
2
DNB
56
2
Financhill
Back

ProPhase Labs 10K Form

Sell
15

PRPH
ProPhase Labs

Last Price:
$0.63
Seasonality Move:
15.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PRPH News And Ratings

See the #1 stock for the next 7 days that we like better than PRPH

PRPH Financial Statistics

Sales & Book Value

Annual Sales: $44.4M
Cash Flow: $-4.2M
Price / Cash Flow: 0
Annual Sales: $2.00
Price / Book: 0.39

Profitability

EPS (TTM): -1.54000
Net Income (TTM): $-27.8M
Gross Margin: $16.2M
Return on Equity: -59.59%
Return on Assets: -30.23%

ProPhase Labs Earnings Forecast

Key ProPhase Labs Financial Ratios

  • The Gross Profit Margin over the past 27 years for PRPH is 36.59%.
  • The Selling, General & Administrative Expenses for PRPH have been equal to 77.74% of Gross Profit Margin.
  • The Research & Development expenses have been 3.19% of Revenue.
  • The Interest Expense is -7.60% of Operating Income.
  • The Net Earning history of PRPH is -37.81% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 15 years.

ProPhase Labs Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PRPH
CUSIP: 74345W
Website: prophaselabs.com

Debt

Debt-to-Equity Ratio: 0.45
Current Ratio: 1.47
Quick Ratio: 1.12

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PRPH Technical Analysis vs Fundamental Analysis

Sell
15
ProPhase Labs (PRPH) is a Sell

Is ProPhase Labs a Buy or a Sell?

  • ProPhase Labs stock is rated a Sell
    The current ProPhase Labs [PRPH] share price is $0.63. The Score for PRPH is 15, which is 70% below its historic median score of 50, and infers higher risk than normal.